Anebulo Pharmaceuticals, Inc. (ANEB)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Peers in Healthcare
Anebulo Pharmaceuticals, Inc. has no peer companies in this window.
Recent press releases
Anebulo Pharmaceuticals, Inc. has not issued a press release in this window.
SEC filings
All filings →Anebulo Pharmaceuticals, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Anebulo Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.